165 related articles for article (PubMed ID: 33202318)
1. Structural heterogeneity of a human norovirus vaccine candidate.
Devant JM; Hansman GS
Virology; 2021 Jan; 553():23-34. PubMed ID: 33202318
[TBL] [Abstract][Full Text] [Related]
2. Heterologous expression of human norovirus GII.4 VP1 leads to assembly of T=4 virus-like particles.
Devant JM; Hofhaus G; Bhella D; Hansman GS
Antiviral Res; 2019 Aug; 168():175-182. PubMed ID: 31145925
[TBL] [Abstract][Full Text] [Related]
3. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
Malm M; Tamminen K; Vesikari T; Blazevic V
Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
[TBL] [Abstract][Full Text] [Related]
4. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
[TBL] [Abstract][Full Text] [Related]
5. Nanobody binding to a conserved epitope promotes norovirus particle disassembly.
Koromyslova AD; Hansman GS
J Virol; 2015 Mar; 89(5):2718-30. PubMed ID: 25520510
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.
Chen W; Kang T; Yuan R; Shao C; Jing S
Biotechnol Lett; 2020 Jul; 42(7):1211-1218. PubMed ID: 32088791
[TBL] [Abstract][Full Text] [Related]
7. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
8. GII.P16-GII.2 Recombinant Norovirus VLPs Polarize Macrophages Into the M1 Phenotype for Th1 Immune Responses.
Han JC; Li QX; Fang JB; Zhang JY; Li YQ; Li SZ; Cheng C; Xie CZ; Nan FL; Zhang H; Li ZX; Jin NY; Zhu GZ; Lu HJ
Front Immunol; 2021; 12():781718. PubMed ID: 34868056
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
Malm M; Vesikari T; Blazevic V
Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
[TBL] [Abstract][Full Text] [Related]
10. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
11. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.
Lindesmith LC; Beltramello M; Donaldson EF; Corti D; Swanstrom J; Debbink K; Lanzavecchia A; Baric RS
PLoS Pathog; 2012; 8(5):e1002705. PubMed ID: 22615565
[TBL] [Abstract][Full Text] [Related]
12. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Malm M; Heinimäki S; Vesikari T; Blazevic V
Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
[TBL] [Abstract][Full Text] [Related]
13. Expression and purification of norovirus virus like particles in Escherichia coli and their immunogenicity in mice.
Huo Y; Wan X; Ling T; Wu J; Wang W; Shen S
Mol Immunol; 2018 Jan; 93():278-284. PubMed ID: 28802994
[TBL] [Abstract][Full Text] [Related]
14. Chimeric GII.3/GII.6 norovirus capsid (VP1) proteins: characterization by electron microscopy, trypsin sensitivity and binding to histo-blood group antigens.
Ma S; Zheng L; Liu J; Wang W; Ma J; Cheng X; Ge L; Wang M; Huo Y; Shen S
Arch Virol; 2018 Dec; 163(12):3265-3273. PubMed ID: 30143876
[TBL] [Abstract][Full Text] [Related]
15. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
Malm M; Tamminen K; Vesikari T; Blazevic V
Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
[TBL] [Abstract][Full Text] [Related]
16. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
17. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.
Kim SH; Chen S; Jiang X; Green KY; Samal SK
J Virol; 2014 Sep; 88(17):9718-27. PubMed ID: 24920815
[TBL] [Abstract][Full Text] [Related]
18. Linear epitope binding antibodies against GII.3 Norovirus exhibit no histo-blood group antigens (HBGAs) blocking effects.
Ma S; Zhang F; Zheng L; Liu J; Ma J; Chen X; Yang Z; Wang W; Li L; Wang M; Huo Y
Virus Genes; 2019 Jun; 55(3):280-289. PubMed ID: 30725444
[TBL] [Abstract][Full Text] [Related]
19. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display.
Koho T; Ihalainen TO; Stark M; Uusi-Kerttula H; Wieneke R; Rahikainen R; Blazevic V; Marjomäki V; Tampé R; Kulomaa MS; Hytönen VP
Eur J Pharm Biopharm; 2015 Oct; 96():22-31. PubMed ID: 26170162
[TBL] [Abstract][Full Text] [Related]
20. Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.
Koromyslova AD; Devant JM; Kilic T; Sabin CD; Malak V; Hansman GS
J Virol; 2020 Jun; 94(13):. PubMed ID: 32321816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
